SPIMACO Reports SAR 133.5M Net Profit in the Six Months 2026
SPIMACO 2070.SA | 0.00 |
On 2026-07-29 16:06:04 (Saudi Time), Saudi Pharmaceutical Industries and Medical Appliances Corp. announced its Interim financial results for the six months ended on June 30, 2026.
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 492.9 | 400.8 | 22.979 | 423.8 | 16.304 |
| Gross Profit (Loss) | 240.1 | 194.1 | 23.699 | 236.1 | 1.694 |
| Operational Profit (Loss) | 88.7 | 61.4 | 44.462 | 87.5 | 1.371 |
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 68.4 | 32.6 | 109.815 | 65.1 | 5.069 |
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 69.1 | 43 | 60.697 | 63.5 | 8.818 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Sales/Revenue | 916.7 | 885.6 | 3.511 |
| Gross Profit (Loss) | 476.2 | 423 | 12.576 |
| Operational Profit (Loss) | 176.2 | 145.9 | 20.767 |
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 133.5 | 103.5 | 28.985 |
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 132.6 | 122.8 | 7.98 |
| Total Shareholders Equity (after Deducting Minority Equity) | 1,688.4 | 1,503.7 | 12.283 |
| Profit (Loss) per Share | 1.12 | 0.87 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| Accumulated Losses | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
Year-on-Year Performance Drivers
For the six-month period ending 30 June 2026, sales/revenue increased 3.511% YoY to SAR 916.7 million (from SAR 885.6 million), driven primarily by a 55.9% rise in contract manufacturing services revenue (SAR 16.6 million) and an 85% surge in international sector sales (SAR 45.4 million). Net profit attributable to shareholders rose 28.985% YoY to SAR 133.5 million (from SAR 103.5 million), supported by a 20.767% increase in operating profit (SAR 30.3 million) resulting from higher revenues and improved operational efficiency through reduction in certain expense items, as well as an 18.6% decrease in finance costs amounting to SAR 9.2 million.
Quarter-on-Quarter Performance Drivers
QoQ revenue rose 16.304% to SAR 492.9 million, driven by a 12.2% increase in private and government sector sales (up SAR 46.9 million) and a 57.9% surge in international sector sales (up SAR 22.2 million). Net profit attributable to shareholders grew 5.069% QoQ to SAR 68.4 million, supported by higher revenues and a 70.8% decrease in impairment loss on financial assets (down SAR 13.7 million) due to improved collections, partially offset by an increase in operating expenses.
Other Items
Saudi Pharmaceutical Industries and Medical Appliances Corp. reported an unmodified conclusion from its external auditor with no additional comments or qualifications noted. No accumulated losses were reported. Total shareholders' equity (after deducting minority equity) stood at SAR 1,688.4 million as of the current period, compared to SAR 1,503.7 million in the same period of the prior year, representing a 12.283% increase. Earnings per share for the current period were SAR 1.12, up from SAR 0.87 in the same period of the prior year. Certain comparative figures have been reclassified to conform to the current period's presentation.
Original announcement:
https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=97075&anCat=1&cs=2070&locale=arAttached PDF document link:
https://www.saudiexchange.sa/Resources/fsPdf/4962_387_2026-07-29_16-00-08_en.pdfImportant Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.